Impact of doxorubicin on survival in advanced ovarian cancer.
about
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancerDocetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerSafety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.Current management of epithelial ovarian carcinoma: a review.Scope of nanotechnology in ovarian cancer therapeutics.Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.Primary ovarian cancer chemotherapy: current standards of careDocetaxel: promising and novel combinations in ovarian cancer.First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidencePegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicinA phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysisThe human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicinA dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerPharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.Activity of anthracyclines in refractory ovarian cancer: recent experience and review.Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience.Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.Injectable supramolecular hydrogels fabricated from PEGylated doxorubicin prodrug and α-cyclodextrin for pH-triggered drug delivery
P2860
Q24198096-9585C938-B1A8-4272-AF68-6E5BDD05518DQ28346751-734290CC-58C4-43AB-8037-BE7EA089D1BBQ33372127-E392D9CA-65E0-4324-A323-5D352AF8C3FAQ33959810-421C6BBB-B3FE-4C99-B844-AB70EA807AABQ34075216-FFC7D3DB-A2E8-426C-932C-17CD19E71A29Q34734502-36279AFC-10E1-4724-9DBB-1C3644656AF4Q35602173-50E3E45B-EB29-4679-B9D3-8759704388C0Q35602190-8D0A188C-97B0-46FA-9AF1-229B0E4B0047Q36115739-F39E3707-7C76-4BA1-A369-55DB0A9A2D1BQ36430920-D20B699F-F2C5-4744-8BC5-D270D96A669CQ36484521-1AC57E89-75CC-4189-856A-9B05DD6D0EF3Q36564944-F52774BE-269A-44AB-AB82-699C03269288Q36644381-3F27316B-B7E0-40E7-BD8C-03DC85EBBEFEQ36644450-AD8E72A5-4667-4D3A-BE0E-53B0935168AAQ36728989-A3E2C074-3D7D-414C-A1E0-EC95510B454DQ37857281-BCEC3B52-1CA2-456E-9E12-3977BE16E406Q38728680-0446BE0E-CE18-4B31-A70D-AA65BCE5E7D9Q41552408-D42C880A-7FF0-427F-8C4F-749354FADB89Q42416643-8A97E7F2-D6C7-40EF-B05F-05C90FE025B5Q43848133-5CFDA39A-0EC2-4019-BE3B-08CFE80C82E1Q57366400-27752F29-524D-4485-B8A5-A97F06BED989
P2860
Impact of doxorubicin on survival in advanced ovarian cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Impact of doxorubicin on survival in advanced ovarian cancer.
@en
Impact of doxorubicin on survival in advanced ovarian cancer.
@nl
type
label
Impact of doxorubicin on survival in advanced ovarian cancer.
@en
Impact of doxorubicin on survival in advanced ovarian cancer.
@nl
prefLabel
Impact of doxorubicin on survival in advanced ovarian cancer.
@en
Impact of doxorubicin on survival in advanced ovarian cancer.
@nl
P1476
Impact of doxorubicin on survival in advanced ovarian cancer.
@en
P2093
P304
P356
10.1200/JCO.1995.13.3.726
P407
P577
1995-03-01T00:00:00Z